• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYC
Click for more information
1.81% $1.36

CYCLOPHARM LIMITED - Announcements

Market Cap $166.7M  ! watchlist Created with Sketch. Add to my watchlist

Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's... Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The Company distributes its products in approximately 65 countries.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
CYC Preliminary Final ReportPRICE SENSITIVE27/02/19
CYC CYC Update - R&D Tax Incentive, USFDA, German LitigationPRICE SENSITIVE24/01/19
CYC CANM Endorses TechnegasPRICE SENSITIVE19/12/18
CYC Positive USFDA Meeting - Technegas sales expected in 2019PRICE SENSITIVE12/10/18
CYC CYC Half Yearly Reports and AccountsPRICE SENSITIVE23/08/18
CYC Cyclopharm 2018 First Half Preliminary Headline UpdatePRICE SENSITIVE08/08/18
CYC Announcement of buy-back - Appendix 3CPRICE SENSITIVE29/05/18
CYC CYC 2018 AGM PresentationPRICE SENSITIVE29/05/18
CYC Managing Director's Address to ShareholdersPRICE SENSITIVE29/05/18
CYC Chairman's Address to ShareholdersPRICE SENSITIVE29/05/18
CYC Better Defining Airways Disease with TechnegasPRICE SENSITIVE17/05/18
CYC Cyclopharm Acquires Scandinavian Distribution BusinessPRICE SENSITIVE07/05/18
CYC 40 Patient Milestone Achieved For Technegas USFDA TrialPRICE SENSITIVE29/03/18
CYC Preliminary Final ReportPRICE SENSITIVE26/02/18
CYC Dividend/Distribution - CYCPRICE SENSITIVE26/02/18
CYC CYC CEO Presentation 2017 Australian Microcap ConferencePRICE SENSITIVE18/10/17
CYC Technegas USFDA Clinical Trial - Patient Enrolment UnderwayPRICE SENSITIVE26/09/17
CYC Cyclopharm acquires European distribution businessPRICE SENSITIVE20/09/17
CYC Advancing Molecular Imaging in NSWPRICE SENSITIVE19/09/17
CYC Half Yearly Report and AccountsPRICE SENSITIVE28/08/17
CYC Nuclear imaging trial aiming to clear up airway diagnosisPRICE SENSITIVE18/08/17
CYC CYC Entitlement Offer BookletPRICE SENSITIVE14/06/17
CYC Entitlement OfferPRICE SENSITIVE05/06/17
CYC CYC - Positive Results of China Clinical TrialPRICE SENSITIVE01/06/17
CYC Announcement of buy-back - Appendix 3CPRICE SENSITIVE09/05/17
CYC Managing Director's Address to ShareholdersPRICE SENSITIVE09/05/17
CYC Cyclopharm Amended 2016 Preliminary Financial ReportPRICE SENSITIVE27/02/17
CYC Preliminary Final ReportPRICE SENSITIVE22/02/17
CYC CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTSPRICE SENSITIVE06/02/17
CYC CYC Achieves USFDA Agreement For Technegas Trial DesignPRICE SENSITIVE23/11/16
CYC Cyclopharm Business Update on Significant Milestones-CYC.AX PRICE SENSITIVE13/10/16
CYC Appendix 4D and Half Year Accounts-CYC.AX PRICE SENSITIVE19/08/16
CYC CYC Signs Agreement with the Canadian Association of Nuc Med-CYC.AX PRICE SENSITIVE27/06/16
CYC Trading Update & Record Technegas Order Received from China-CYC.AX PRICE SENSITIVE21/06/16
CYC Announcement of buy-back - Appendix 3C-CYC.AX PRICE SENSITIVE11/05/16
CYC Cyclopharm to Proceed Independently with FDA Trials-CYC.AX PRICE SENSITIVE10/05/16
CYC Preliminary Final ReportPRICE SENSITIVE24/02/16
CYC Technegas COPD Trial UpdatePRICE SENSITIVE29/01/16
CYC Cyclopharm receives insurance settlementPRICE SENSITIVE31/12/15
CYC Cyclopharm signs Term Sheet with Jubilant DraximagePRICE SENSITIVE14/09/15
CYC Half Yearly Report and AccountsPRICE SENSITIVE26/08/15
CYC Preliminary Final ReportPRICE SENSITIVE19/02/15
CYC Update on Cyclotron FacilityPRICE SENSITIVE16/09/14
CYC Half Yearly Report and AccountsPRICE SENSITIVE29/08/14
CYC Results of MediationPRICE SENSITIVE26/08/14
CYC Cyclotron Facility Suffers Significant Water DamagePRICE SENSITIVE20/06/14
CYCCyclopharm to cease Cyclotron commercial operationsPRICE SENSITIVE28/03/14
CYCPreliminary Final ReportPRICE SENSITIVE28/02/14
CYCJapanese Regulatory Approval receivedPRICE SENSITIVE25/10/13
CYCHalf Yearly Report and AccountsPRICE SENSITIVE28/08/13
CYCTechnegas May Facilitate Earlier Diagnosis of COPDPRICE SENSITIVE02/05/13
CYCCyclopharm Develops New Nuclear Medicine TechnologyPRICE SENSITIVE18/04/13
CYCPreliminary Final ReportPRICE SENSITIVE26/02/13
CYCTechnegas Clinical Trial - First Patient EnrolledPRICE SENSITIVE19/11/12
CYCOffer BookletPRICE SENSITIVE09/11/12
CYCRenounceable IssuePRICE SENSITIVE09/11/12
CYCTrading HaltPRICE SENSITIVE06/11/12
CYCHalf Yearly Report and AccountsPRICE SENSITIVE30/08/12
CYCCyclopharm to Establish Operations in QueenslandPRICE SENSITIVE24/08/12
CYCCyclopharm Files Claim Against ANSTOPRICE SENSITIVE28/06/12
CYCPreliminary Final ReportPRICE SENSITIVE29/02/12
CYCCyclopharm Receives Approval from United States FDAPRICE SENSITIVE13/12/11
CYCOffer Booklet for Renounceable Rights IssuePRICE SENSITIVE18/11/11
CYCRenounceable Rights Issue and Sale of Unmarketable ParcelsPRICE SENSITIVE04/11/11
CYCRenewal of Debt Facility with National Australia BankPRICE SENSITIVE03/11/11
CYCHalf Yearly Report and AccountsPRICE SENSITIVE31/08/11
CYCTrading UpdatePRICE SENSITIVE29/07/11
CYCPreliminary Final ReportPRICE SENSITIVE28/02/11
CYCClinical Protocol Approval from US FDAPRICE SENSITIVE22/02/11
CYCCyclopet sells commercial FDG dosesPRICE SENSITIVE16/12/10
CYCCyclopet receives TGA LicensePRICE SENSITIVE03/12/10
CYCHalf Yearly Report and AccountsPRICE SENSITIVE31/08/10
CYCRegulatory Approval in ChinaPRICE SENSITIVE25/05/10
CYCPreliminary Final ReportPRICE SENSITIVE25/02/10
CYCCyclopharm settles claim for US$1.8mPRICE SENSITIVE11/12/09
CYCCyclotron delivered to Macquarie University HospitalPRICE SENSITIVE09/11/09
CYCHalf Yearly Report and AccountsPRICE SENSITIVE27/08/09
CYCCyclopharm enters into Medical Imaging Joint VenturePRICE SENSITIVE29/07/09
CYCCompany UpdatePRICE SENSITIVE28/04/09
CYCPreliminary Final ReportPRICE SENSITIVE26/02/09
CYCLodgement of application to sell Technegas in United StatesPRICE SENSITIVE22/12/08
CYC Preliminary Final Report
27/02/19PRICE SENSITIVE
CYC CYC Update - R&D Tax Incentive, USFDA, German Litigation
24/01/19PRICE SENSITIVE
CYC CANM Endorses Technegas
19/12/18PRICE SENSITIVE
CYC Positive USFDA Meeting - Technegas sales expected in 2019
12/10/18PRICE SENSITIVE
CYC CYC Half Yearly Reports and Accounts
23/08/18PRICE SENSITIVE
CYC Cyclopharm 2018 First Half Preliminary Headline Update
08/08/18PRICE SENSITIVE
CYC Announcement of buy-back - Appendix 3C
29/05/18PRICE SENSITIVE
CYC CYC 2018 AGM Presentation
29/05/18PRICE SENSITIVE
CYC Managing Director's Address to Shareholders
29/05/18PRICE SENSITIVE
CYC Chairman's Address to Shareholders
29/05/18PRICE SENSITIVE
CYC Better Defining Airways Disease with Technegas
17/05/18PRICE SENSITIVE
CYC Cyclopharm Acquires Scandinavian Distribution Business
07/05/18PRICE SENSITIVE
CYC 40 Patient Milestone Achieved For Technegas USFDA Trial
29/03/18PRICE SENSITIVE
CYC Preliminary Final Report
26/02/18PRICE SENSITIVE
CYC Dividend/Distribution - CYC
26/02/18PRICE SENSITIVE
CYC CYC CEO Presentation 2017 Australian Microcap Conference
18/10/17PRICE SENSITIVE
CYC Technegas USFDA Clinical Trial - Patient Enrolment Underway
26/09/17PRICE SENSITIVE
CYC Cyclopharm acquires European distribution business
20/09/17PRICE SENSITIVE
CYC Advancing Molecular Imaging in NSW
19/09/17PRICE SENSITIVE
CYC Half Yearly Report and Accounts
28/08/17PRICE SENSITIVE
CYC Nuclear imaging trial aiming to clear up airway diagnosis
18/08/17PRICE SENSITIVE
CYC CYC Entitlement Offer Booklet
14/06/17PRICE SENSITIVE
CYC Entitlement Offer
05/06/17PRICE SENSITIVE
CYC CYC - Positive Results of China Clinical Trial
01/06/17PRICE SENSITIVE
CYC Announcement of buy-back - Appendix 3C
09/05/17PRICE SENSITIVE
CYC Managing Director's Address to Shareholders
09/05/17PRICE SENSITIVE
CYC Cyclopharm Amended 2016 Preliminary Financial Report
27/02/17PRICE SENSITIVE
CYC Preliminary Final Report
22/02/17PRICE SENSITIVE
CYC CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTS
06/02/17PRICE SENSITIVE
CYC CYC Achieves USFDA Agreement For Technegas Trial Design
23/11/16PRICE SENSITIVE
CYC Cyclopharm Business Update on Significant Milestones-CYC.AX
13/10/16PRICE SENSITIVE
CYC Appendix 4D and Half Year Accounts-CYC.AX
19/08/16PRICE SENSITIVE
CYC CYC Signs Agreement with the Canadian Association of Nuc Med-CYC.AX
27/06/16PRICE SENSITIVE
CYC Trading Update & Record Technegas Order Received from China-CYC.AX
21/06/16PRICE SENSITIVE
CYC Announcement of buy-back - Appendix 3C-CYC.AX
11/05/16PRICE SENSITIVE
CYC Cyclopharm to Proceed Independently with FDA Trials-CYC.AX
10/05/16PRICE SENSITIVE
CYC Preliminary Final Report
24/02/16PRICE SENSITIVE
CYC Technegas COPD Trial Update
29/01/16PRICE SENSITIVE
CYC Cyclopharm receives insurance settlement
31/12/15PRICE SENSITIVE
CYC Cyclopharm signs Term Sheet with Jubilant Draximage
14/09/15PRICE SENSITIVE
CYC Half Yearly Report and Accounts
26/08/15PRICE SENSITIVE
CYC Preliminary Final Report
19/02/15PRICE SENSITIVE
CYC Update on Cyclotron Facility
16/09/14PRICE SENSITIVE
CYC Half Yearly Report and Accounts
29/08/14PRICE SENSITIVE
CYC Results of Mediation
26/08/14PRICE SENSITIVE
CYC Cyclotron Facility Suffers Significant Water Damage
20/06/14PRICE SENSITIVE
CYCCyclopharm to cease Cyclotron commercial operations
28/03/14PRICE SENSITIVE
CYCPreliminary Final Report
28/02/14PRICE SENSITIVE
CYCJapanese Regulatory Approval received
25/10/13PRICE SENSITIVE
CYCHalf Yearly Report and Accounts
28/08/13PRICE SENSITIVE
CYCTechnegas May Facilitate Earlier Diagnosis of COPD
02/05/13PRICE SENSITIVE
CYCCyclopharm Develops New Nuclear Medicine Technology
18/04/13PRICE SENSITIVE
CYCPreliminary Final Report
26/02/13PRICE SENSITIVE
CYCTechnegas Clinical Trial - First Patient Enrolled
19/11/12PRICE SENSITIVE
CYCOffer Booklet
09/11/12PRICE SENSITIVE
CYCRenounceable Issue
09/11/12PRICE SENSITIVE
CYCTrading Halt
06/11/12PRICE SENSITIVE
CYCHalf Yearly Report and Accounts
30/08/12PRICE SENSITIVE
CYCCyclopharm to Establish Operations in Queensland
24/08/12PRICE SENSITIVE
CYCCyclopharm Files Claim Against ANSTO
28/06/12PRICE SENSITIVE
CYCPreliminary Final Report
29/02/12PRICE SENSITIVE
CYCCyclopharm Receives Approval from United States FDA
13/12/11PRICE SENSITIVE
CYCOffer Booklet for Renounceable Rights Issue
18/11/11PRICE SENSITIVE
CYCRenounceable Rights Issue and Sale of Unmarketable Parcels
04/11/11PRICE SENSITIVE
CYCRenewal of Debt Facility with National Australia Bank
03/11/11PRICE SENSITIVE
CYCHalf Yearly Report and Accounts
31/08/11PRICE SENSITIVE
CYCTrading Update
29/07/11PRICE SENSITIVE
CYCPreliminary Final Report
28/02/11PRICE SENSITIVE
CYCClinical Protocol Approval from US FDA
22/02/11PRICE SENSITIVE
CYCCyclopet sells commercial FDG doses
16/12/10PRICE SENSITIVE
CYCCyclopet receives TGA License
03/12/10PRICE SENSITIVE
CYCHalf Yearly Report and Accounts
31/08/10PRICE SENSITIVE
CYCRegulatory Approval in China
25/05/10PRICE SENSITIVE
CYCPreliminary Final Report
25/02/10PRICE SENSITIVE
CYCCyclopharm settles claim for US$1.8m
11/12/09PRICE SENSITIVE
CYCCyclotron delivered to Macquarie University Hospital
09/11/09PRICE SENSITIVE
CYCHalf Yearly Report and Accounts
27/08/09PRICE SENSITIVE
CYCCyclopharm enters into Medical Imaging Joint Venture
29/07/09PRICE SENSITIVE
CYCCompany Update
28/04/09PRICE SENSITIVE
CYCPreliminary Final Report
26/02/09PRICE SENSITIVE
CYCLodgement of application to sell Technegas in United States
22/12/08PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.36 		Change
-0.025(1.81%) 		Mkt cap ! $166.7M
Open High Low Value Volume
$1.38 $1.38 $1.36 $63.10K 45.77K

Buyers (Bids)

No. Vol. Price($)
1 499 $1.36
 

Sellers (Offers)

Price($) Vol. No.
$1.40 39732 2
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
$1.38 		  Change
-0.025 ( 1.61 %)
Open High Low Volume
$1.38 $1.38 $1.37 4328
Last updated 15.46pm 15/11/2024 ?
CYC (ASX) Chart

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.